Lack of evidence for a link between latanoprost use and malignant melanoma: An analysis of safety databases and a review of the literature

British Journal of Ophthalmology

Volumn 95, Issue 11, 2011, Pages 1490-1495

  Tressler, Charles S ^a   Wiseman, Robert L ^a   Dombi, Theresa M ^a   Jessen, Bart ^a   Huang, Kui ^a   Kwok, Kenneth K ^a   Wirostko, Barbara M ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; DORZOLAMIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL; MELANIN; MONOPHENOL MONOOXYGENASE; TIMOLOL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CHOROID MELANOMA; CILIARY BODY TUMOR; CONTROLLED STUDY; DRUG SAFETY; ENZYME INDUCTION; EYE MELANOMA; EYE PAIN; EYE TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAOCULAR MELANOMA; IRIS DISEASE; IRIS MELANOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOCYTIC NEVUS; MELANOGENESIS; MELANOMA; MELANOSIS; META ANALYSIS; MITOSIS; OPTIC NERVE TUMOR; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHOOL CHILD; SYSTEMATIC REVIEW; TREATMENT DURATION; TUMOR VOLUME; UVEA MELANOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; EYE NEOPLASMS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; SKIN NEOPLASMS; TIMOLOL; YOUNG ADULT;

EID: 80054965527     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.193987     Document Type: Review

References (34)

1. de Vries E, Bray FI, Coebergh JW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003;107:119-26. (Pubitemid 37100095)
2. Isager P, Osterlind A, Engholm G, et al. Uveal and conjunctival malignant melanoma in Denmark, 1943-97: incidence and validation study. Ophthalmic Epidemiol 2005;12:223-32. (Pubitemid 41702804)
3. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009;129:1666-74.
4. Inskip PD, Devesa SS, Fraumeni JF Jr. Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control 2003;14:251-7. (Pubitemid 36656335)
5. McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005;103:1000-7. (Pubitemid 40270077)
6. Hurst EA, Harbour JW, Cornelius LA. Ocular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol 2003;139:1067-73. (Pubitemid 36994834)
7. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:956-61. (Pubitemid 36560496)
8. Hu DN, Yu GP, McCormick SA, et al. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 2005;140:612-17.
9. Virgili G, Gatta G, Ciccolallo L, et al. Incidence of uveal melanoma in Europe. Ophthalmology 2007;114:2309-15.
10. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53(Suppl 1):S93-105.
11. Stjernschantz JW, Albert DM, Hu DN, et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002;47(Suppl 1): S162-75. (Pubitemid 35232231)
12. Anon. Xalatan [Package Insert]. New York, NY: Pfizer Inc, 2009.
13. Esteve E, Beau-Salinas F, Esteve L, et al. [Melanoma during latanoprost therapy: three cases]. Ann Dermatol Venereol 2009;136:60-1.
14. Weinreb RN, Toris CB, Gabelt BT, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002;7(Suppl 1):S53-64. (Pubitemid 35232219)
15. Crowston JG, Lindsey JD, Aihara M, et al. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest Ophthalmol Vis Sci 2004;45:3555-9. (Pubitemid 39298573)
16. Ocklind A, Lake S, Wentzel P, et al. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci 1996;37:716-26.
17. Scott G, Leopardi S, Printup S, et al. Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity. J Invest Dermatol 2004;122:1214-24. (Pubitemid 38651097)
18. Scott G, Jacobs S, Leopardi S, et al. Effects of PGF2alpha on human melanocytes and regulation of the FP receptor by ultraviolet radiation. Exp Cell Res 2005;304:407-16. (Pubitemid 40321119)
19. Fricke A, McClelland L, Scott G. The PGF(2alpha) receptor FP is lost in nevi and melanoma. Pigment Cell Melanoma Res 2010;23:141-3.
20. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41(Suppl 2):S129-38. (Pubitemid 27154537)
21. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 2004;22:957-65. (Pubitemid 39037958)
22. Prota G. Regulatory mechanisms of melanogenesis: beyond the tyrosinase concept. J Invest Dermatol 1993;100:156S-61S. (Pubitemid 23051691)
23. Drago F, Marino A, La Manna C. alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res 1999;68:85-90. (Pubitemid 29084576)
24. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res 2000;70:563-9.
25. Lindsey JD, Jones HL, Hewitt EG, et al. Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost. Arch Ophthalmol 2001;119:853-60. (Pubitemid 32530314)
26. Stjernschantz J, Ocklind A, Wentzel P, et al. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes. Acta Ophthalmol Scand 2000;78:618-22.
27. Cagigrigoriu A, Boero E, Carenini AB, et al. Do antiglaucomatous prostaglandins induce melanogenesis in human conjunctiva?: an impression cytology pilot study. J Glaucoma 2010;19:44-50.
28. Cracknell KP, Grierson I, Hogg P. Morphometric effects of long-term exposure to latanoprost. Ophthalmology 2007;114:938-48.
29. Cracknell KP, Grierson I, Hogg P, et al. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies. Exp Eye Res 2003;77:721-30. (Pubitemid 37373586)
30. Arranz-Marquez E, Teus MA, Saornil MA, et al. Analysis of irises with a latanoprost-induced change in iris color. Am J Ophthalmol 2004;138:625-30. (Pubitemid 39420492)
31. Albert DM, Gangnon RE, Grossniklaus HE, et al. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides. Arch Ophthalmol 2008;126:626-31. (Pubitemid 351679556)
32. Albert DM, Gangnon RE, Zimbric ML, et al. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients. Arch Ophthalmol 2004;122:1680-5. (Pubitemid 39473414)
33. Landreville S, Agapova OA, Harbour JW. Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol 2008;4:629-36.
34. Belmar-Lopez C, Mancheno-Corvo P, Saornil MA, et al. Uveal vs. cutaneous melanoma. Origins and causes of the differences. Clin Transpl Oncol 2008;10:137-42.